Accuracy of a faecal immunochemical test in patients under colonoscopy surveillance of colorectal adenoma and cancer
Abstract
Background: Surveillance of colorectal neoplasia place great strain on colonoscopy resources, and faecal immunochemical tests (FIT) are under-investigated for this purpose. The aim of this study was to report the outcome of FIT among patients scheduled for post-polypectomy and post-resection colorectal cancer (CRC) surveillance.
Methods: Patients scheduled for colonoscopy surveillance at five endoscopy units in mid-Sweden in 2016–2020 were eligible. They provided a faecal sample from 2 separate days, which were analysed by iFOBT QuikRead go® (Aidian Oy). Both the colonoscopies, and the FIT analyses were conducted by staff blinded to the other.
Results: Out of 216 included patients, 157 (73%) underwent both a complete colonoscopy and had at least one FIT analysed prior to the examination. The indication for surveillance was previous adenoma in 69 (44%) and post-resection CRC in 88 (56%) patients. Two (1%) in the CRC surveillance group were diagnosed with a metachronous CRC, whereas 49 (56%) patients in the CRC surveillance, and 17 (25%) in the adenoma group had no pathology identified at colonscopy (P < 0.001). The proportion of patients diagnosed with adenomas requiring surveillance according to European Society of Gastrointestinal Society (ESGE) guidelines 2020 was 6 (7%) in the post-CRC resection versus 7 (10%) in the adenoma surveillance group (P = 0.4). Based on one FIT and at cut-off 10 µg Hb/g, sensitivity for CRC was 100%, specificity 83% (95% confidence interval [CI]: 77–89), Positive Predictive Value (PPV) 7% (−2 to 16) and Negative Predictive Value (NPV) 100%. All patients with an adenoma requiring surveillance had a FIT below this cut-off. Adding a second FIT decreased the specificity.
Conclusion: Larger studies to evaluate the accuracy and consequences of using FIT for surveillance of colorectal neoplasia are needed. FIT may be more interesting for post-resection CRC surveillance than follow-up of adenoma.
Downloads
References
2. Hassan C, Antonelli G, Dumonceau JM, Regula J, Bretthauer M, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – update 2020. Endoscopy. 2020;52:687–700. doi: 10.1055/a-1185-3109
3. Waldmann E, Kammerlander A, Gessl I, Penz D, Majcher B, Hinterberger A, et al. New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. United European Gastroenterol J. 2021;9:947–54. doi: 10.1002/ueg2.12119
4. Atkin W, Cross AJ, Kralj-Hans I, MacRae E, Piggott C, Pearson S, et al. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study. Health Technol Assess. 2019;23:1–84. doi: 10.3310/hta23010
5. Maclean W, Zahoor Z, O’Driscoll S, Piggott C, Whyte MB, Rockall T, et al. Comparison of the QuikRead go((R)) point-of-care faecal immunochemical test for haemoglobin with the FOB Gold Wide((R)) laboratory analyser to diagnose colorectal cancer in symptomatic patients. Clin Chem Lab Med. 2022;60:101–8. doi: 10.1515/cclm-2021-0655
6. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev 2015; 24: 24–6. doi: 10.1097/CEJ.0000000000000016
7. Hassan C, Quintero E, Dumonceau JM, Regula J, Brandao C, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2013;45:842–51. doi: 10.1055/s-0033-1344548
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015; 351: h5527. doi: 10.1136/bmj.h5527
9. Skåne R. Prislistor Södra sjukvårdsregionen 2022 [cited 2022 April, 29]. Available from: https://vardgivare.skane.se/patientadministration/avgifter-och-prislistor/prislistor-sodra-sjukvardsregionen/.
10. Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, et al. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. Gut. 2019;68:1642–52. doi: 10.1136/gutjnl-2018-317297
11. Hazazi R, Rozen P, Leshno M, Levi Z, Samuel Z, Waked A, et al. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy? Aliment Pharmacol Ther. 2010;31:523–33. doi: 10.1111/j.1365-2036.2009.04202.x
12. Terhaar sive Droste JS, van Turenhout ST, Oort FA, van der Hulst RW, Steeman VA, Coblijn U, et al. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterol. 2012;12:94. doi: 10.1186/1471-230X-12-94
13. Atkin W, Wooldrage K, Brenner A, Martin J, Shah U, Perera S, et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol. 2017;18:823–34. doi: 10.1016/S1470-2045(17)30187-0
14. Fuccio L, Rex D, Ponchon T, Frazzoni L, Dinis-Ribeiro M, Bhandari P, et al. New and recurrent colorectal cancers after resection: a systematic review and meta-analysis of endoscopic surveillance studies. Gastroenterology. 2019;156:1309–23 e3. doi: 10.1053/j.gastro.2018.12.006
15. van Lanschot MCJ, van Leerdam ME, Lansdorp-Vogelaar I, Doets S, Nagtegaal ID, Schreurs HW, et al. Yield of surveillance colonoscopies 1 year after curative surgical colorectal cancer resections. Clin Gastroenterol Hepatol. 2019;17:2285–93. doi: 10.1016/j.cgh.2019.02.026
16. Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology. 2016;150:758–68 e11. doi: 10.1053/j.gastro.2016.01.001
17. Djinbachian R, Dubé A-J, Durand M, Camara LR, Panzini B, Bouchard S, et al. Adherence to post-polypectomy surveillance guidelines: a systematic review and meta-analysis. Endoscopy. 2019;51:673–83.
18. Dong J, Wang LF, Ardolino E, Feuerstein JD. Real-world compliance with the 2020 U.S. Multi-Society Task Force on Colorectal Cancer polypectomy surveillance guidelines: an observational study. Gastrointest Endosc. 2023; 97: 350–6 e3. doi: 10.1016/j.gie.2022.08.020
19. Johnson MR, Grubber J, Grambow SC, Maciejewski ML, Dunn-Thomas T, Provenzale D, et al. Physician non-adherence to colonoscopy interval guidelines in the veterans affairs healthcare system. Gastroenterology. 2015;149:938–51. doi: 10.1053/j.gastro.2015.06.026
20. Kerrison RS, Sheik-Mohamud D, McBride E, Whitaker KL, Rees C, Duffy S, et al. Patient barriers and facilitators of colonoscopy use: A rapid systematic review and thematic synthesis of the qualitative literature. Prev Med. 2021;145:106413. doi: 10.1016/j.ypmed.2020.106413
21. Bonello B, Ghanouni A, Bowyer HL, MacRae E, Atkin W, Halloran SP, et al. Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy. BMC Gastroenterol. 2016;16:113. doi: 10.1186/s12876-016-0517-1
22. von Wagner C, Verstraete W, Hirst Y, Nicholson BD, Stoffel ST, Laszlo H. Public preferences for using quantitative faecal immunochemical test versus colonoscopy as diagnostic test for colorectal cancer: evidence from an online survey. BJGP Open. 2020;4. doi: 10.3399/bjgpopen20X101007
23. Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupe VMH. Screening for colorectal cancer with fecal immunochemical testing with and without postpolypectomy surveillance colonoscopy: a cost-effectiveness analysis. Ann Intern Med. 2017;167:544–54. doi: 10.7326/M16-2891
24. Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med. 2019;170:319–29. doi: 10.7326/M18-2390
25. Cross AJ, Robbins EC, Pack K, Stenson I, Kirby PL, Patel B, et al. Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. Gut. 2020;69:1645–58. doi: 10.1136/gutjnl-2019-320036
26. Wieszczy P, Kaminski MF, Franczyk R, Loberg M, Kobiela J, Rupinska M, et al. Colorectal cancer incidence and mortality after removal of adenomas during screening colonoscopies. Gastroenterology. 2020;158:875–83 e5. doi: 10.1053/j.gastro.2019.09.011
27. O’Reilly SM, MacNally S, O’Donoghue D, Mooney T, Fitzpatrick P, Mulcahy HE, et al. Correlation of fecal immunochemical testing levels with pathology results in a national colorectal cancer screening program. Clin Transl Gastroenterol. 2021;12:e00277. doi: 10.14309/ctg.0000000000000277
28. Pilonis ND, Bugajski M, Wieszczy P, Rupinski M, Pisera M, Pawlak E, et al. Participation in competing strategies for colorectal cancer screening: a randomized health services study (PICCOLINO Study). Gastroenterology. 2021;160:1097–105. doi: 10.1053/j.gastro.2020.11.049
29. Wassie MM, Young GP, Winter JM, Cock C, Bampton P, Rahman M, et al. Multiple negative fecal immunochemical tests reduce risk of advanced neoplasia in a colonoscopy surveillance program. Clin Gastroenterol Hepatol 2023 Jan 5;S1542-3565(23)00002-2. doi: 10.1016/j.cgh.2022.12.024
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
